Comparing Ibrutinib vs Tacrolimus
| Ibrutinib | Tacrolimus |
|
|---|
| Ibrutinib | Tacrolimus |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Ibrutinib is an oral tablet that may be taken once daily to treat certain types of cancers in adults or to treat chronic Graft Versus Host disease in adults and children older than 1 year. It works... View more |
Prescription only
Prescribed for Organ Transplant - Rejection Reversal, Organ Transplant - Rejection Prophylaxis, Graft Versus Host Disease, Crohn's Disease, Nephrotic Syndrome. Tacrolimus may also be used for... View more |
Related suggestions Graft Versus Host Disease
Popular comparisons
|
|||||||
| More about Ibrutinib | More about Tacrolimus | ||||||||
| Ratings & Reviews | |||||||||
|
Ibrutinib has an average rating of 6.9 out of 10 from a total of 87 ratings on Drugs.com. 63% of reviewers reported a positive effect, while 26% reported a negative effect. |
Tacrolimus has an average rating of 7.7 out of 10 from a total of 50 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 14% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Ibrutinib side effects |
View all Tacrolimus side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
Lower cost generic |
||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Tacrolimus prices |
||||||||
| Dosage Forms | |||||||||
|
N/A |
|
||||||||
| Brand Names | |||||||||
| Imbruvica | Astagraf XL, Envarsus XR, Prograf | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
6 hours |
21.2 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 504 drugs are known to interact with Ibrutinib:
|
A total of 872 drugs are known to interact with Tacrolimus:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
|
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
November 13, 2013 |
April 08, 1994 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Kesimpta
Kesimpta is used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated ...
Jaypirca
Jaypirca (pirtobrutinib) is a cancer medicine used to treat types of CLL, SLL, and MCL. Includes ...
Calquence
Calquence (acalabrutinib) is used to treat chronic lymphocytic leukemia (CLL), and mantle cell ...
Brukinsa
Brukinsa is used to treat adults with mantle cell lymphoma, Waldenström’s macroglobulinemia, ma ...
Imbruvica
Imbruvica (ibrutinib) is used to treat chronic lymphocytic leukemia (CLL), small lymphocytic ...
Venclexta
Venclexta may be used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ...
Acalabrutinib
Acalabrutinib (Calquence) is used to treat chronic lymphocytic leukemia (CLL), and mantle cell ...
Venetoclax
Venetoclax (brand name Venclexta) may be used to treat CLL, SLL, or AML in those aged 75 years or ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.